These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors. Crook ED, Preddie DC. Ethn Dis; 2002 Sep 19; 12(4):S3-49-52. PubMed ID: 12477155 [Abstract] [Full Text] [Related]
3. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control]. Shionoiri H, Yasuda G, Takizawa T, Shionoiri F. Nihon Rinsho; 2005 Jun 19; 63 Suppl 6():394-9. PubMed ID: 15999741 [No Abstract] [Full Text] [Related]
4. Hypertension arm of ADVANCE defines extent of renal protection using perindopril/indapamide in type 2 diabetics. Cardiovasc J Afr; 2008 Jun 19; 19(4):226. PubMed ID: 18776973 [No Abstract] [Full Text] [Related]
5. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?]. Luño J, Valderrábano F. An Med Interna; 1998 Nov 19; 15(11):567-71. PubMed ID: 9882851 [No Abstract] [Full Text] [Related]
6. [Threatened diabetic nephropathy. Early administration of ACE inhibitors and AT1 blockers]. Einecke U. MMW Fortschr Med; 2002 Apr 11; 144(15):14. PubMed ID: 12004443 [No Abstract] [Full Text] [Related]
7. Clinical practice. Nephropathy in patients with type 2 diabetes. Remuzzi G, Schieppati A, Ruggenenti P. N Engl J Med; 2002 Apr 11; 346(15):1145-51. PubMed ID: 11948275 [No Abstract] [Full Text] [Related]
8. Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn? Hollenberg NK. Arch Intern Med; 2004 Jan 26; 164(2):125-30. PubMed ID: 14744834 [No Abstract] [Full Text] [Related]
9. Prevention of end-stage renal disease due to type 2 diabetes. Hostetter TH. N Engl J Med; 2001 Sep 20; 345(12):910-2. PubMed ID: 11565525 [No Abstract] [Full Text] [Related]
10. Treating diabetic nephropathy--are there only economic issues? Mitch WE. N Engl J Med; 2004 Nov 04; 351(19):1934-6. PubMed ID: 15516698 [No Abstract] [Full Text] [Related]
11. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?]. Os I, Stenehjem A, Høieggen A, Draganov B, Jenssen T, Holdaas H. Tidsskr Nor Laegeforen; 2002 Apr 10; 122(9):918-20. PubMed ID: 12082835 [Abstract] [Full Text] [Related]
12. [Hypertension therapy for type 2 diabetics]. Bönner G. MMW Fortschr Med; 2007 Jun 07; 149(23):45, 47-8. PubMed ID: 18062579 [No Abstract] [Full Text] [Related]
15. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection. Blankfield RP. N Engl J Med; 2002 Feb 28; 346(9):705-7. PubMed ID: 11870250 [No Abstract] [Full Text] [Related]
16. Advances in the treatment of diabetic renal disease: focus on losartan. Rayner B. Curr Med Res Opin; 2004 Mar 28; 20(3):333-40. PubMed ID: 15025842 [Abstract] [Full Text] [Related]
17. Angiotensin-Il-receptor blockers and nephropathy in patients with type 2 diabetes. Farquhar D. CMAJ; 2001 Nov 13; 165(10):1379. PubMed ID: 11760990 [No Abstract] [Full Text] [Related]
18. [Effect of blood glucose and blood pressure control on progression of diabetic nephropathy]. Schwarz C, Oberbauer R. Wien Klin Wochenschr; 2000 Nov 10; 112(21):907-11. PubMed ID: 11144004 [Abstract] [Full Text] [Related]
19. [Prediction, screening and treatment of renal complications of diabetes]. Marre M, Larger E. Rev Prat; 2001 Oct 15; 51(16):1769-75. PubMed ID: 11795120 [Abstract] [Full Text] [Related]